Amarin Corp Plc (AMRN)

[KCSVEN]

Yes and no, assuming Vascepa gets Anchor indication that is highly accurate but in the here and now Vascepa has had a hard time gaining share quickly and cost is a large factor as you can see the heavy rebates and coupons, etc... So a generic version of Lovaza is even cheaper than Lovaza tier 2.

The concern over whether AMRN's patents can hold up is also out there since Pronova's patents cannot hold up. of course, AMRN will have 40 patents and Pronova is basically trying to defend 1 patent so not as concerned on that.

On the positives
1)Generics can't sell to Anchor, which is the main market
2)Lovaza has side effects
3)GSK may want to pony up a BO of AMRN to replace accelerated Lovaza sales losses.